Twist Bioscience (TWST) AI Stock Analysis

• Market Cap: $1.67B
• Dividend Yield: N/A
• Average Volume (3M): 1.23M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.53
• Revenue Growth: 22.72%
• EPS Growth: 62.11%
• Country: US
• Employees: 923
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.33
• Shares Outstanding: 60,360,924
• 10 Day Avg. Volume: 2,022,278
• 30 Day Avg. Volume: 1,225,552
• PEG Ratio: 0.00
• Price to Book (P/B): 5.55
• Price to Sales (P/S): 8.38
• P/FCF Ratio: -37.89
• Enterprise Value/Market Cap: 1.25
• Enterprise Value/Revenue: 7.80
• Enterprise Value/Gross Profit: 25.23
• Enterprise Value/Ebitda: -16.04
• 1Y Price Target: $36.29
• Price Target Upside: 31.34% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8

• Rating: 61 Neutral
• Price Target: $29.00 ▲(4.96% Upside)

Twist Bioscience's overall stock score reflects strong revenue growth and strategic board appointments, but is tempered by ongoing profitability challenges and bearish technical indicators. The earnings call provided positive insights into operational improvements, yet valuation remains a concern due to negative earnings.

Positive Factors

Earnings

NGS drove the quarter, delivering $55M and beating expectations.

Profitability

Profitability was well ahead of expectations.

Strategic Initiatives

Management signaled a shift in focus back to top-line growth, including new product launches intended to expand the SynBio market opportunity.

Negative Factors

Macro Environment

Macro headwinds have impacted new customer ramps and project orders for existing customers.

Revenue Guidance

TWST shares were down sharply in response to the F3Q meet and narrowing of guide.

SynBio Performance

SynBio was notably soft, posting just 7% growth to $35M and missing estimates.

Twist Bioscience Business Overview & Revenue Model

Company Description

Twist Bioscience Corporation is a biotechnology company specializing in synthetic biology and DNA synthesis. Headquartered in San Francisco, California, the company focuses on providing high-quality, cost-effective DNA synthesis solutions to a variety of sectors, including pharmaceuticals, agriculture, and data storage. Twist Bioscience's core products include its synthetic DNA products, which are utilized for applications such as gene therapy, antibody discovery, and next-generation sequencing, among others.

How the Company Makes Money

Twist Bioscience generates revenue primarily through the sale of its synthetic DNA products and services. The company operates on a revenue model that is driven by the demand for custom DNA synthesis, which serves a diverse clientele from research institutions to commercial enterprises. Key revenue streams include the sale of oligonucleotides, gene fragments, and complete genes, as well as DNA libraries for various applications in research and development. Additionally, Twist has formed significant partnerships and collaborations with major companies and institutions in the biotech and pharmaceutical industries, which further enhances its market reach and contributes to its earnings. The company also benefits from recurring revenue through long-term contracts and agreements with its clients, solidifying its financial stability and growth potential.

Twist Bioscience Financial Statement Overview

Summary

Twist Bioscience is experiencing strong revenue growth, but faces challenges with profitability and cash flow. The balance sheet is solid with a high equity ratio and low debt, yet the negative ROE and operating losses indicate areas needing improvement.

Income Statement

Twist Bioscience has demonstrated strong revenue growth with a TTM revenue increase of 11.09% over the previous annual period. However, the company is facing profitability challenges, with negative net profit and EBIT margins indicating ongoing operating losses. The gross profit margin of 46.7% in the TTM suggests a solid ability to cover direct costs, but the company's net profit margin remains negative at -54.96%.

Balance Sheet

The company's balance sheet shows a solid equity position with an equity ratio of 73.91% in the TTM, indicating financial stability and relatively low leverage. The debt-to-equity ratio is manageable at 0.18, suggesting conservative use of debt. However, the negative ROE at -43.42% highlights the inability to generate profit from equity capital currently.

Cash Flow

Cash flow analysis reveals a challenging situation with negative operating and free cash flows over the recent periods. The TTM free cash flow to net income ratio and operating cash flow to net income ratio are not favorable, indicating inefficiencies in converting income to cash. However, there is a slight improvement in free cash flow, which is a positive sign.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	266.22M	312.97M	245.11M	203.56M	132.33M	90.10M
Gross Profit	82.34M	133.35M	89.73M	84.23M	51.71M	28.69M
EBITDA	-129.55M	-176.71M	-174.15M	-191.55M	-143.91M	-132.09M
Net Income	-85.19M	-208.73M	-204.62M	-217.86M	-152.10M	-139.93M
Balance Sheet
Total Assets	643.61M	614.32M	776.40M	961.38M	702.10M	398.88M
Cash, Cash Equivalents and Short-Term Investments	250.80M	276.40M	336.41M	504.97M	477.86M	290.00M
Total Debt	78.15M	85.03M	94.07M	94.91M	62.92M	35.98M
Total Liabilities	165.41M	141.63M	152.97M	171.99M	121.28M	62.62M
Stockholders Equity	478.20M	472.69M	623.43M	789.38M	580.82M	336.26M
Cash Flow
Free Cash Flow	-68.71M	-69.17M	-170.25M	-226.24M	-139.31M	-152.12M
Operating Cash Flow	-51.13M	-64.09M	-142.47M	-124.39M	-112.24M	-142.25M
Investing Cash Flow	-13.64M	-3.07M	50.61M	-232.93M	156.16M	-114.65M
Financing Cash Flow	26.59M	6.89M	911.00K	270.53M	329.18M	303.73M

Twist Bioscience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 27.63
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TWST, the sentiment is Negative. The current price of 27.63 is below the 20-day moving average (MA) of 32.84, below the 50-day MA of 34.13, and below the 200-day MA of 40.36, indicating a bearish trend. The MACD of -2.43 indicates Positive momentum. The RSI at 34.45 is Neutral, neither overbought nor oversold. The STOCH value of 15.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TWST.

Twist Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SHC	68 Neutral	$3.99B	167.98	5.14%	―	2.40%	-40.03%
ILMN	67 Neutral	$14.57B	12.00	68.11%	―	-3.32%	―
TWST	61 Neutral	$1.67B	―	-17.58%	―	22.72%	62.11%
GRAL	58 Neutral	$1.18B	―	-62.22%	―	30.47%	-26.63%
Sector *	57 Neutral	£5.16B	4.90	-44.55%	2.18%	28.89%	-10.08%
EXAS	52 Neutral	$7.75B	―	-35.51%	―	12.56%	-464.28%
GH	49 Neutral	$6.83B	―	-4584.47%	―	28.74%	18.25%

Twist Bioscience Corporate Events

Twist Bioscience Appoints Trynka Shineman Blake to Board

On August 5, 2025, Twist Bioscience appointed Trynka Shineman Blake to its Board of Directors, where she will also serve on the Audit Committee. Ms. Shineman Blake, with her extensive experience in corporate governance and digital transformation, is expected to contribute significantly to Twist’s strategic direction as the company aims for adjusted EBITDA breakeven and continued innovation. Her previous leadership roles at Vistaprint highlight her ability to drive growth and innovation, aligning with Twist’s customer-centric growth strategy.

The most recent analyst rating on (TWST) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Twist Bioscience stock, see the TWST Stock Forecast page.